683
After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).
 potential therapeutic event: receive 
Please tell me event type and its trigger word from given type options. Output format is "type: trigger".  Option: adverse event, potential therapeutic event 
Text: {0} 
Answer:
 potential therapeutic event: receive 